Keros Therapeutics (KROS) Receivables (2021 - 2025)
Keros Therapeutics (KROS) has disclosed Receivables for 4 consecutive years, with $3.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables rose 30.09% year-over-year to $3.6 million, compared with a TTM value of $3.6 million through Dec 2025, up 30.09%, and an annual FY2025 reading of $3.6 million, up 30.09% over the prior year.
- Receivables was $3.6 million for Q4 2025 at Keros Therapeutics, up from $3.5 million in the prior quarter.
- Across five years, Receivables topped out at $18.0 million in Q4 2021 and bottomed at $4000.0 in Q2 2024.
- Average Receivables over 4 years is $5.6 million, with a median of $2.7 million recorded in 2024.
- Peak annual rise in Receivables hit 395300.0% in 2025, while the deepest fall reached 30.09% in 2025.
- Year by year, Receivables stood at $18.0 million in 2021, then plummeted by 99.21% to $143000.0 in 2023, then soared by 1817.48% to $2.7 million in 2024, then surged by 30.09% to $3.6 million in 2025.
- Business Quant data shows Receivables for KROS at $3.6 million in Q4 2025, $3.5 million in Q3 2025, and $15.8 million in Q2 2025.